By InvitationNot Applicable

Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence

United States2,000 participantsStarted 2022-09-14

Plain-language summary

This is a multi-center retrospective analysis of consecutive adult patients with cryptogenic stroke patients following a comprehensive workup for the underlying stroke etiology. Patients will be eligible for inclusion if the index stroke event occurred between 1/1/2016 and 06/30/2022.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Consecutive adult patients (18 yrs of age or older) diagnosed with cryptogenic stroke despite complete neurodiagnostic workup, including the following:
✓. Left ventricular ejection fraction greater than or equal to 20%

Exclusion criteria

✕. Patients with an established stroke mechanism that is diagnosed prior to or at the time of the index stroke event. Examples include but are not limited to:
✕. Patients without follow-up information at 30 days (although patients who expired within 90 days of stroke are still eligible for inclusion)
✕. Patients enrolled in a randomized clinical trial in which antithrombotic group is blinded to the investigator
✕. Transient ischemic attack
✕. Primary intracerebral hemorrhage

What they're measuring

Prevalence of potential embolic sources

Timeframe: through study completion, an average of 2 years

The odds of recurrent stroke, major bleeding (according to the International Society of Thrombosis and Hemostasis), and/or death will be estimated across the cohort, with annualized event rates also calculated

Timeframe: At any point during follow-up over a minimum of 90 days after stroke (average of 2 years)

Number of patients treated with antiplatelet, anticoagulant, or combination antithrombotic therapy

Timeframe: through study completion, an average of 2 years

Trial details

NCT IDNCT06398366

SponsorThe Cooper Health System

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-05-30

View on ClinicalTrials.gov More Cryptogenic Stroke trials

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Consecutive adult patients (18 yrs of age or older) diagnosed with cryptogenic stroke despite complete neurodiagnostic workup, including the following:
✓. Left ventricular ejection fraction greater than or equal to 20%

Exclusion criteria

✕. Patients with an established stroke mechanism that is diagnosed prior to or at the time of the index stroke event. Examples include but are not limited to:
✕. Patients without follow-up information at 30 days (although patients who expired within 90 days of stroke are still eligible for inclusion)
✕. Patients enrolled in a randomized clinical trial in which antithrombotic group is blinded to the investigator
✕. Transient ischemic attack
✕. Primary intracerebral hemorrhage

What they're measuring

Prevalence of potential embolic sources

Timeframe: through study completion, an average of 2 years

Timeframe: At any point during follow-up over a minimum of 90 days after stroke (average of 2 years)

Number of patients treated with antiplatelet, anticoagulant, or combination antithrombotic therapy

Timeframe: through study completion, an average of 2 years